Background and Aims. Owing to its unique anatomical structure and metabolism, epicardial adipose tissue (EAT) has attracted amount of attention in coronary artery disease (CAD) research. Here, we analyzed differences in proteome composition in epicardial (EAT) and subcutaneous adipose tissues (SAT) from patients with or without CAD. Methods. EAT and SAT samples were collected from 6 CAD patients and 6 non-CAD patients. Isobaric Tagging for Relative and Absolute Quantitation (iTRAQ) analysis combined with liquid chromatography tandem-mass spectrometry (LC-MS/MS) was performed to identify the differentially expressed proteins. Results. In total, 2348 proteins expressed in EAT and 2347 proteins expressed in SAT were separately identified. 385 differentially expressed proteins were found in EAT and 210 proteins were found in SAT in CAD patients compared to non-CAD patients. Many proteins differentially expressed in EAT of CAD patients were involved in biological functions associated with CAD development such as cell-to-cell signaling and interaction, inflammatory response, and lipid metabolism. Differential expressions of proteins (MMP9, S100A9, and clusterin) in EAT or SAT were involved in several signaling pathways such as mitochondrial dysfunction, acute phase inflammation, and LXR/RXR activation, which was confirmed by western blotting, and similar results were obtained. Conclusions. The largest profiles of differentially expressed proteins in EAT and SAT between CAD patients and non-CAD patients were identified. The significant signal pathways, mitochondrial dysfunction, and LXR/RXR activation, which differential proteins were involved in, were firstly found to play roles in EAT of CAD patients, and clusterin was firstly found to be upregulated in EAT of CAD patients.
Background: Hydroxysafflor yellow A (HSYA) is the main active monomer of safflower yellow (SY), an adjunct for cardiovascular/cerebrovascular diseases. Our previous studies demonstrated that SY/HSYA improved non-alcoholic fatty liver disease (NAFLD) in obese mice; however, the precise mechanisms remain unclear. This study aimed to investigate the molecular targets and mechanisms by which HSYA ameliorates NAFLD. Methods: Male C57BL/6J mice were fed a high-fat diet for 8 weeks to induce diet-induced obesity (DIO), followed by HSYA treatment (100 mg/kg/d) for 8 weeks and antibiotic or non-antibiotic treatment for another 5 weeks. Body weight, OGTT, IPITT, liver histology, liver transcriptomics, and fecal metagenomics were assessed. In vitro, HepG2 cells were treated with 400 μM of palmitic acid (PA) to induce steatosis, followed by HSYA treatment and/or cluster of differentiation 36 (CD36) overexpression. Results: HSYA significantly reduced body weight and fat mass and improved glucose metabolism in DIO mice. HSYA also alleviated hepatic steatosis, which was partly abolished by antibiotic treatment, indicating partial dependence on gut microbiota. Metagenomics revealed that HSYA increased the abundance of Akkermansia muciniphila, which negatively correlated with NAFLD scores. HSYA significantly downregulated CD36 and its upstream signal transducer and activator of transcription 1 (STAT1) protein expression in liver tissue by 59.5% and 35.4%, respectively. Similarly, HSYA reduced CD36 and phospho-STAT1 expression in PA-treated HepG2 cells, and these effects were abolished by CD36 overexpression. Conclusions: HSYA improved NAFLD by remodeling gut microbiota and by inhibiting the STAT1/CD36 pathway, thereby reducing fatty acid uptake in hepatocytes.